Clinical trial
A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
NCT03122548 is registered in ClinicalTrials.gov with Aduro Biotech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
- Lead sponsor
- Aduro Biotech, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 14, 2017
- Completion date
- January 31, 2018
- Enrollment
- 5 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma